Table 1 Baseline demographics and disease characteristics of patients who participated in the vaccination substudy and of those who did not
Participated n = 29 | Did not participate n = 17 | Total cohort 2a n = 46 | |
|---|---|---|---|
Age at enrolment, years | 4.2 (0.9) | 3.8 (1.2) | 4.1 (1.0) |
Female, n (%) | 16 (55.2) | 12 (70.6) | 28 (60.9) |
Weight, kg | 18.4 (3.6) | 18.0 (3.5) | 18.2 (3.5) |
Weight categories, kg, n (%) | |||
< 25 | 27 (93.1) | 16 (94.1) | 43 (93.5) |
25–50 | 2 (6.9) | 1 (5.9) | 3 (6.5) |
≥ 50 | 0 | 0 | 0 |
Race, n (%) | |||
White | 29 (100.0) | 15 (88.2) | 44 (95.7) |
Black/African American | 0 | 1 (5.9) | 1 (2.2) |
Other | 0 | 1 (5.9) | 1 (2.2) |
Geographic region, n (%) | |||
South America | 4 (13.8) | 4 (23.5) | 8 (17.4) |
Europe | 25 (86.2) | 11 (64.7) | 36 (78.3) |
Rest of world | 0 | 2 (11.8) | 2 (4.3) |
Duration of JIA, years | 0.8 (1.0) | 0.8 (1.0) | 0.8 (1.0) |
JIA disease onset categories, n (%) | |||
Polyarthritis RF− | 18 (62.1) | 12 (70.6) | 29 (63.0) |
Polyarthritis RF+ | 0 | 2 (11.8) | 3 (6.5) |
Extended oligoarthritis | 8 (27.6) | 2 (11.8) | 10 (21.7) |
Psoriatic arthritis | 3 (10.3) | 1 (5.9) | 4 (8.7) |
No. of active joints | 10.0 (6.4) | 8.1 (5.2) | 9.3 (6.0) |
No. of joints with limitation of motion | 9.6 (5.9) | 7.1 (4.8) | 8.7 (5.6) |
CHAQ-DI score | 1.0 (0.7) | 1.2 (0.6) | 1.1 (0.7) |
Parent global assessment score | 37.0 (22.9) | 41.4 (26.0) | 38.6 (23.9) |
Physicians global assessment score | 50.2 (16.1) | 41.9 (20.4) | 47.1 (18.0) |
CRP, mg/dL | 0.8 (1.4) | 2.3 (3.4) | 1.3 (2.4) |
MTX dose ay Day 1, mg/m2/week | n = 22 13.5 (4.5) | n = 14 12.0 (2.3) | n = 37 12.9 (3.8) |
Prednisone dose at Day 1, mg/kg/day | n = 3 0.2 (0.0) | n = 5 0.3 (0.2) | n = 8 0.2 (0.1) |